Probiotix Health PLC - New Partnership Agreement in Slovakia
ProBiotix Health plc
("ProBiotix" or the "Company")
New Partnership Agreement in
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a new partnership agreement with
ProBiotix has secured a commercial cooperation with iProbio to supply its patented probiotic strain LPLDL® for a new cardiometabolic health food supplement branded as CARDIObiom+®, a product developed by the iProbio consumer brand of PerBiotiX s.r.o., a leading Slovak based probiotics company.
Cardiovascular disease mortality in
After an extensive evaluation of clinically validated ingredients in the cardiometabolic space, iProbio selected LPLDL® for its robust clinical evidence in supporting healthy cholesterol levels. CARDIObiom+® combines LPLDL® with a standardised polyphenol-rich extract of lemon verbena (Aloysia citrodora) and hibiscus (Hibiscus sabdariffa), together with vitamin D3 and vitamin B1, in a dual-capsule daily dose designed to support cholesterol metabolism, lipid and glucose metabolism, and overall metabolic balance.
The new product will initially be distributed in
1 Source: European Society of Cardiology
"Increasing awareness of the need to focus on cardiovascular health is critical, and with this partnership agreement we are very pleased that we can help advance further awareness and increase sales in new geographic territories."
Martin Haranta, CEO of iProbio, added: "CARDIObiom+® represents a natural next step for iProbio. After more than 40 years of microbiome research, we wanted to expand our targeted probiotic portfolio into the field of cardiometabolic health - a segment where there is strong scientific evidence as well as a clear consumer need.
"LPLDL® is a probiotic strain with clinically validated effects supporting cholesterol metabolism, and our partnership with ProBiotix Health has provided us with confidence both in the scientific foundation and in supply reliability. The product launch on World Hypertension Day also allowed us to naturally connect with the ongoing conversation among Slovak consumers about heart health and metabolic balance. We look forward to further developing this collaboration."
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the
For further information, please contact:
|
ProBiotix Health plc |
|
|
|
|
|
|
|
|
|
|
|
AlbR Capital Limited Aquis Corporate Adviser and Broker |
Tel: 020 7469 0930 |
|
|
|
Notes to Editors:
ProBiotix Health is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.
The Company has a unique approach; discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.
About iProbio
iProbio is the consumer brand of PerBiotiX s. r. o., a Slovak life sciences company specialising in personalised probiotics, targeted probiotics, prebiotics, flavobiotics and essential food supplements. The company is headquartered in Čadca,
The company was co-founded by
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE